Aims & Scope

Aims:

International Journal of Lymphoma Therapeutics (IJLT) is a gold open-access, peer-reviewed publication providing a global perspective and experience with modern therapies targeting Hodgkin’s Disease, Non-Hodgkin’s Lymphomas, and Chronic Lymphocytic Leukemia. The journal provides an international forum for the dissemination of high-quality scientific insights and impactful advances to academics, clinicians, pharmacists, allied healthcare professionals, and the public worldwide. IJLT seeks to publish comprehensive thematic reviews by leading experts in the field that highlight current and emerging treatment strategies, including CAR T cell therapy, antibody-drug conjugates, T cell engagers, checkpoint inhibitors, therapies targeting signaling pathways, and approaches involving transcriptional and epigenetic regulation. This journal is published quarterly online by Scilight Press.

Scope:

International Journal of Lymphoma Therapeutics (IJLT) focuses on meaningful advances utilizing modern therapeutics. Articles address the scientific rationale, mechanism of action, clinical efficacy, treatment toxicity, and potential synergy of novel therapies with complementary treatment approaches. The journal incorporates multidisciplinary perspective spanning hematologic oncology, radiation oncology, pharmacy, and pathology. Representative case reports are also featured to best illustrate the real-world application of state-of-the-art therapies. IJLT serves as a timely resource for the global lymphoma community.